65th ASH Annual Meeting & Exposition: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Fundamental Science, Acute Myeloid Malignancies, AML, Biological therapies, Translational Research, Clinical Research, Combination therapy, Diseases, real-world evidence, Therapies, Immunotherapy, Myeloid Malignancies, Natural Killer (NK) Cell Therapies

Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)

Moderators:

Melinda Ann Biernacki, MD, Fred Hutchinson Cancer Center and Tanja A. Gruber, MD, PhD, Stanford University School of Medicine

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

163

Identification of Acute Myeloid Leukemia Cell Surface Therapeutic Targets Using Single Cell RNA Sequencing Supported By Surface Proteomics

Véronique Lisi¹^*, Banafsheh Khakipoor, PhD²^*, Azer Farah, PhD²^*, Marie-Eve Bordeleau, PhD³^*, Eric Audemard, PhD³^*, Arnaud Metois, MSc³^*, Louis Theret, PhD³^*, Jean-François Spinella, PhD³^*, Jalila Chagraoui, PhD³^*, Ossama Moujaber, PhD³^*, Laure Mallinger³^*, Isabel Boivin³^*, Nadine Mayotte, MS³^*, Azadeh Hajmirza, PhD³^*, Eric Bonneil, PhD³^*, Francois Béliveau, PhD⁴^*, Albert Feghali³^*, Geneviève Boucher³^*, Patrick Gendron³^*, Frederic Barabe, MD⁵, Sebastien Lemieux, PhD³^*, Guillaume Richard-Carpentier, MD, FRCPC⁶, Josée Hébert, MD³^*, Philippe Roux, PhD³^*, Guy Sauvageau, MD/PhD³ and Vincent-Philippe Lavallee, MD/PhD²

¹Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, QC, Canada
²CHU Sainte-Justine, Montreal, QC, Canada
³Institut de recherche en Immunologie et Cancer, Université de Montréal, Montreal, QC, Canada
⁴Banque de cellules leucémiques du Québec, Montréal, QC, Canada
⁵Hôpital de l'Enfant-Jésus, Division of Hematology and Medical Oncology, CHU de Québec - Université Laval, Québec, QC, Canada
⁶Princess Margaret Cancer Center, Toronto, ON, CAN

2:15 PM

164

Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens

Amanda Halfond, MSc¹^*, Matthew H Ung, PhD²^*, Julia Etchin, PhD¹^*, Yonina Keschner¹^*, Julia DiFazio¹^*, Alyssa Pyclik¹^*, Guy Mundelboim¹^*, Gary Ge, PhD¹^*, John Lydeard, PhD¹^* and Tirtha Chakraborty, PhD¹^*

¹Vor Biopharma, Cambridge, MA
²Quantitative Biology, Vor Biopharma, Cambridge, MA

2:30 PM

165

Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

Eduardo Sabino Magalhaes, MD¹^*, Stefan Hubner²^*, Brandon D. Brown, MD³^*, Yihua Qiu⁴^* and Steven M. Kornblau, MD⁴

¹Department of Ageing Biology/ERIBA, University Medical Center Groningen, Groningen, Netherlands
²John Sealy School of Medicine, The University of Texas Medical Branch (UTMB), Galveston, TX
³Department of Pediatrics, MD Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2:45 PM

166

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A-Rearranged RAS Pathway-Mutant Acute Leukemia

Nastassja Scheidegger, MD^1,2,3^*, Gabriela Alexe, PhD^2,3^*, Delan Khalid^2,3^*, Rhonda E Ries, MA⁴^*, Jim Wang, MS⁵^*, Todd A. Alonzo, PhD^5,6^*, Jennifer Perry, PhD²^*, Scott A Armstrong, MD, PhD⁷, Soheil Meshinchi, MD, PhD⁸, Yana Pikman, MD^2,3 and Kimberly Stegmaier, MD^2,9

¹Department of Pediatric Oncology, Children’s University Hospital of Zurich, Zurich, Switzerland
²Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA
³The Broad Institute of MIT and Harvard, Cambridge, MA
⁴Translational Sciences and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
⁵Children's Oncology Group, Monrovia, CA
⁶Univ. of Southern California Keck School of Med., Monrovia, CA
⁷Pediatric Oncology, Dana-Farber Cancer Institute, Boston
⁸Translational Sciences and Therapeutics, Fred Hutchinson Cancer Research Center, Seattle, WA
⁹The Broad Institute of MIT and Harvard, Cambridge

3:00 PM

167

Targeting SLC3A2 Sensitizes AML Cells Towards NK Cell-Mediated Killing

Kishan Bellamkonda, PhD¹^*, Ramprasad Ramakrishnan, PhD¹^*, Somadri Ghosh²^*, Katrin Reinbach¹^* and Marcus Järås, PhD¹^*

¹Division of Clinical Genetics, Lund University, Lund, Skåne, Sweden
²Division of Clinical Genetics, Lund University, Lund, Sweden

3:15 PM

168

Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia

Fanny Gonzales, MD, PhD^1,2, Pauline Peyrouze, MS¹^*, Thomas Boyer, MD, PhD¹^*, Soizic Guihard, PhD¹^*, Francois Sevrin, MD¹^*, Djohana Laurent, MS¹^*, Adriana Plesa, MD³^*, Adeline Barthelemy, PhD¹^*, Antonino Bongiovanni, PhD⁴^*, Claude Preudhomme, PharmD, PhD^1,5^*, Nicolas Duployez, PharmD, PhD^1,5^*, Celine Berthon, MD, PhD¹^*, Christophe Roumier, PharmD^1,5^* and Meyling H Cheok, PharmD, PhD¹^*

¹ONCOLILLE - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Univ. Lille, CHU Lille, IRCL, ONCOLILLE, CNRS-UMR9020, Inserm-U1277, Lille, France
²Paediatric Haematology Department, CHU Lille, Lille, France
³Laboratory of Hematology, Hospices Civils de Lyon, Lyon, France
⁴Univ. Lille, CNRS UMR 8204, Inserm U1019, CHU Lille, Institut Pasteur de Lille - CIIL - Center for Infection and Immunity of Lille, Lille, France
⁵Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

617A.O2.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics